Check for updates





Blood 142 (2023) 197-201

The 65th ASH Annual Meeting Abstracts

ORAL ABSTRACTS

637.MYELODYSPLASTIC SYNDROMES - CLINICAL AND EPIDEMIOLOGICAL

Clinical and Genomic-Based Decision Support System to Define the Optimal Timing of Allogeneic Hematopoietic Stem Cell Transplantation in Patients with Myelodysplastic Syndromes (MDS)

Cristina Astrid Tentori, MD¹, Caterina Gregorio, PhD², Marie Robin, MD³, Nico Gagelmann⁴, Carmelo Gurnari, MD⁵, Somedeb Ball, MD⁶, Juan Carlos Caballero Berrocal, MD⁷, Luca Lanino, MD⁸, Saverio D'Amico, MSc¹, Marta Spreafico, PhD², Giulia Maggioni, MD¹, Erica Travaglino, BS¹, Elisabetta Sauta, PhD¹, Manja Meggendorfer, PhD⁹, Lin-Pierre Zhao, MD¹⁰, Massimo Bernardi, MD¹¹, Carmen Di Grazia, MD¹², Luca Vago, MDPhD¹³, Giulia Rivoli, MD¹⁴, Lorenza Maria Borin, MD¹⁵, Patrizia Chiusolo¹⁶, Luisa Giaccone, MD PhD¹⁷, Maria Teresa Voso, MD¹⁸, Jan Philipp Bewersdorf, MD¹⁹, Olivier Nibourel, PhD²⁰, Marina Díaz-Beyá, MD PhD²¹, Andres Jerez, MD²², Francisca Maria Hernandez, MD²³, Kyra Velázquez Kennedy, MD²⁴, Blanca Xicoy, MD²⁵, Marta Ubezio, MD¹, Alessia Campagna, MD¹, Antonio Russo, MD¹, Gabriele Todisco, MD¹, Daniele Mannina, MD¹, Stefania Bramanti¹, Matteo Zampini, PhD¹, Elena Riva, BSc¹, Marilena Bicchieri, PhD¹, Gianluca Asti, MSc¹, Filippo Viviani, MD¹, Alessandro Buizza, MD¹, Benedetta Tinterri, MD¹, Andrea Bacigalupo, MD²⁶, Alessandro Rambaldi, MD²⁷, Francesco Passamonti, MD²⁸, Fabio Ciceri²⁹, Victor Savevski, MEng¹, Armando Santoro, MD³⁰, Najla H Al Ali, MS³¹, David A Sallman, MD³², Francesc Sole, PhD³³, Guillermo Garcia-Manero, MD³⁴, Ulrich Germing³⁵, Shahram Kordasti, MDPhD³⁶, Valeria Santini, MD³⁷, Guillermo Sanz, MD PhD³⁸, Wolfgang Kern, MD⁹, Anne Sophie Kubasch, MD³⁹, Uwe Platzbecker, MD⁴⁰, Maria Diez-Campelo, MD PhD⁴¹, Jaroslaw P. Maciejewski, MD, PhD, FACP⁵, Lionel Ades, MDPhD⁴², Pierre Fenaux, MD PhD⁴³, Torsten Haferlach, MD PhD⁹, Amer M. Zeidan, MBBS, MHS⁴⁴, Gastone Castellani, PhD⁴⁵, Rami S. Komrokji, MD³¹, Francesca Ieva, PhD², Matteo Giovanni Della Porta, MD¹

¹ Humanitas Clinical and Research Center, IRCCS, Rozzano, Italy

²Politecnico di Milano, Milano, Italy

³Hopital Saint-Louis, Paris, France

⁴University Medical Center Hamburg-Eppendorf, Hamburg, Germany, Hamburg, DEU

⁵Department of Translational Hematology and Oncology Research, Taussig Cancer Institute, Cleveland Clinic, Cleveland, OH

⁶Vanderbilt University Medical Center, Nashville, TN

⁷Hematology Department, Hospital Universitario de Salamanca, Salamanca, Spain, Salamanca, ESP

⁸Humanitas Clinical and Research Center, IRCCS, Rozzano, Italy

⁹MLL Munich Leukemia Laboratory, Munich, Germany

¹⁰Department of Hematology and Bone Marrow Transplantation, Hôpital Saint-Louis/Assistance Publique-Hôpitaux de Paris (AP-HP)/University Paris 7, Paris, France, Paris, FRA

¹¹Unit of Hematology and Bone Marrow Transplantation, I.R.C.C.S. Ospedale San Raffaele, Milan, Italy

¹²Hematology and Transplant Center, IRCCS Ospedale Policlinico San Martino, Genua, Italy, Genova, Italy

¹³Hematology and Bone Marrow Transplantation Unit, I.R.C.C.S. Ospedale San Raffaele, Milano, Italy

¹⁴Hematology and Cellular Therapy Division, IRCCS Ospedale Policlinico San Martino, Genova, Genova, Italy

¹⁵Hematology, Ospedale San Gerardo, Monza, Italy, Monza, Italy

¹⁶Dipartimento di Diagnostica per Immagini, Radioterapia Oncologica ed Ematologia, Fondazione Policlinico Universitario Agostino Gemelli IRCCS, Roma, Italy

¹⁷ Univesity of Torino, AOU Città Della Salute E Della Scienza Di Torino, Torino, ITA

¹⁸Department of Biomedicine and Prevention, University of Rome Tor Vergata, Rome, Italy

¹⁹Department of Medicine, Section of Hematology, Yale University, New Haven, CT

²⁰Laboratory of Hematology, CHU Lille, Lille, France, Paris, FRA

²¹ Hematology Department, Hospital Clínic Barcelona, Barcelona, Spain

²²Cleveland Clinic Taussig Cancer Institute, Cleveland, OH

²³Department of Hematology, Hospital Virgen de las Nieves, Granada, Spain

²⁴ Department of Hematology, Ramón y Cajal University Hospital - IRYCIS, Madrid, Spain, Madrid, Spain

ORAL ABSTRACTS

²⁵Hematology Department, Institut Català d'Oncologia, Hospital Universitari Germans Trias i Pujol, Institut de Recerca Contra la Leucèmia Josep Carreras, Universitat Autònoma de Barcelona, Badalona, Spain

²⁶ Dipartimento di Diagnostica per Immagini, Radioterapia Oncologica ed Ematologia, Fondazione Policlinico Universitario A. Gemelli IRCCS, Rome, Italy

²⁷ Department of Oncology and Hematology, University of Milan and Azienda Socio-Sanitaria Territoriale Papa Giovanni XXIII, Bergamo BG, Italy

²⁸ Dipartimento di Oncologia ed Ematologia, Università degli Studi di Milano, Policlinico di Milano, Ospedale Maggiore, Fondazione I.R.C.C.S. Ca Granda, Milano, Italy

²⁹Unit of Hematology and Stem Cell Transplantation, Ospedale San Raffaele, University Vita-Salute San Raffaele, Milan, Italy

³⁰Humanitas Cancer Center, Rozzano, Italy

³¹ Department of Malignant Hematology, Moffitt Cancer Center, Tampa, FL

³²H. Lee Moffitt Cancer Center, Tampa, FL

³³ Myelodysplastic Syndromes Research Group, Josep Carreras Leukaemia Research Institute, ICO-Hospital Germans Trias i Pujol, Universitat Autònoma de Barcelona, Badalona, Spain

³⁴University of Texas MD Anderson Cancer Center, Houston, TX

³⁵Department of Hematology, Oncology and Clinical Immunology, Universitatsklinik Dusseldorf, Dusseldorf, Germany

³⁶King's College London, London, United Kingdom

³⁷ MDS Unit, DMSC, AOU Careggi, University of Florence, Firenze, Italy

³⁸Health Research Institute La Fe, Valencia, Spain, Valencia, Spain

³⁹Department of Hematology, University Hospital of Leipzig, Dresden, Germany

⁴⁰University Leipzig Medical Center, Leipzig, Germany

⁴¹ University Hospital of Salamanca, Salamanca, Spain

⁴²Saint Louis Hospital, APHP, Paris, France

⁴³Department of Hematology, Université de Paris, Saint-Louis Hospital, Paris, France

⁴⁴ Section of Hematology, Department of Internal Medicine, Yale University School of Medicine - Yale Cancer Center, New Haven, CT

⁴⁵Department of Physics and Astronomy (DIFA), Bologna, Italy., Bologna, Italy

Purpose. Allogeneic hematopoietic stem cell transplantation (HSCT) is the only potentially curative treatment for patients with myelodysplastic syndromes (MDS). Several issues must be considered when evaluating the benefits and risks of HSCT for patients with MDS, with the timing of transplantation during the disease course being a crucial question.

Recently the integration of genomic screening (by Molecular International Prognostic Scoring System, IPSS-M) into patient's assessment has resulted into a significant improvement in predicting clinical outcomes with respect to the conventional prognostic score (Revised IPSS, IPSS-R), including better stratification of post-HSCT outcome.

Here, we aimed to develop and validate a Decision Support System to define the optimal timing of HSCT in MDS patients based on clinical and genomic information as provided by IPSS-M vs conventional IPSS-R.

Patients and methods. We studied a retrospective, international cohort of 8,326 patients with MDS for whom complete set of clinical and molecular information was available. Patients were stratified into a learning and validation cohorts (65%, n= 5411 vs. 35%, n=2915). The decision-strategy analysis was divided into two parts. First, we developed a multi-state model to estimate transition hazards between different disease strata. Age and IPSS-R/IPSS-M were used as explanatory variables. The time elapsed between the diagnosis of MDS and HSCT was also considered as covariate in the models, which were further adjusted for disease-modifying therapy (if any). Next, we developed a Semi-Markov multi-state decision model based on microsimulation to compare various transplantation strategies according to the timing of the procedure, conditionally on covariates of interest. The microsimulation strategy simulates a hypothetical randomized clinical trial where subjects are randomized to receive HSCT at different time points. Results were used to estimate the average survival time over an 8-year time horizon (Restricted Mean Survival Time, RMST) for each combination of covariates, and then determine the optimal transplantation policy by compared the different strategies.

Results. When considering patient life expectancy for patients who received a HSCT (Restricted Mean Survival Time, RMST) in the learning cohort, in both scenarios of IPSS-R and IPSS-M based transplantation policies, early disease stage was associated with a better clinical outcome. Indeed, life expectancy after transplantation was higher for younger vs elderly patients (*Figure 1 and 2*). Under an IPSS-R based policy, patients with low-risk disease clearly benefit from a delayed transplantation policy across all age groups, while in patients belonging to intermediate, high/very high risk categories immediate transplantation was associated with a prolonged life expectancy, regardless of age. (*Figure 1*) Considering an IPSS-M based policy, patients with either low and moderate-low risk benefit from a delayed transplantation policy (across all age groups), while in those belonging to moderate-high, high and very high risk categories immediate transplantation was associated with a prolonged life expectancy, and transplantation policy (across all age groups), while in those belonging to moderate-high, high and very high risk categories immediate transplantation was associated with a prolonged life expectancy. *Figure 2*). Importantly, all these results were confirmed in the validation cohort, thus providing evidence for their reliability and generalizability.


Modelling decision analysis on IPSS-M vs. original IPSS-R changed transplantation policy in a significant proportion of patients, resulting in a gain-in-life expectancy under an IPSS-M based policy across all age groups (P<0.001). Specifically, 19% of candidates to be immediately transplanted under an IPSS-R based policy would benefit from a delayed strategy under an IPSS-M based policy, while 21% of candidates to delayed transplantation under an IPSS-R based policy, would benefit from immediate HSCT under an IPSS-M based policy.

We have created a prototype web application for the MDS Transplantation Decision Support System, that allows clinicians to define the best timing for HSCT starting from individual patient demographics, IPSS-R, and IPSS-M information.

Conclusion. We provided evidence for the clinical relevance of including genomic features into the transplantation decision making process, specifically regarding the optimal timing of HSCT, allowing personalizing of the hazards and effectiveness of HSCT in patients with MDS.

Disclosures Meggendorfer: MLL Munich Leukemia Laboratory: Current Employment. Voso: Jazz: Other: Advisory Board; Celgene/BMS: Other: Advisory Board; Astra Zeneca: Speakers Bureau; Novartis: Speakers Bureau; Abbvie: Speakers Bureau; Jazz: Speakers Bureau; Astellas: Speakers Bureau; Novartis: Research Funding; Celgene/BMS: Research Funding, Speakers Bureau; Syros: Other: Advisory Board. Díaz-Beyá: Bristol Myers Squibb: Consultancy, Honoraria; Abbvie: Consultancy, Honoraria; Astellas: Consultancy, Honoraria; Jazz Pharma: Consultancy, Honoraria; Takeda: Consultancy, Honoraria; Novartis: Consultancy, Honoraria. Rambaldi: Abbvie: Honoraria. Passamonti: Novartis, GSK, Bristol Myers Squibb, Celgene, Sierra Oncology, AbbVie, Janssen, Roche, AOP Orphan, Karyopharm, Kyowa Kirin, MEI, Sumitomo: Honoraria; Roche: Consultancy; Abbvie: Consultancy, Honoraria; BMS: Consultancy, Honoraria, Research Funding. Ciceri: ExCellThera: Other: Scientific Advisory Board . Santoro: Gilead: Membership on an entity's Board of Directors or advisory committees, Speakers Bureau; Servier: Membership on an entity's Board of Directors or advisory committees, Speakers Bureau; BMS: Membership on an entity's Board of Directors or advisory committees, Speakers Bureau; Incyte: Consultancy; Sanofi: Consultancy; Pfizer: Membership on an entity's Board of Directors or advisory committees, Speakers Bureau; Eisai: Membership on an entity's Board of Directors or advisory committees, Speakers Bureau; Baver: Membership on an entity's Board of Directors or advisory committees, Speakers Bureau; Merck MSD: Membership on an entity's Board of Directors or advisory committees, Speakers Bureau; Takeda: Speakers Bureau; Roche: Speakers Bureau; Abbvie: Speakers Bureau; Amgen: Speakers Bureau; Celgene (BMS): Speakers Bureau; AstraZeneca: Speakers Bureau; Eli Lilly: Speakers Bureau; Sandoz: Speakers Bureau; Novartis: Speakers Bureau; Arqule: Other. Sallman: Aprea, Jazz: Research Funding; AbbVie, Affimed Gmbh, Gilead, Incyte, Intellisphere, LLC, Molecular Partners AG, PGEN Therapeutics, Inc., Takeda, Zentalis; Advisory board for AvenCell, BlueBird Bio, BMS, Intellia, Jasper Therapeutics, Kite, Magenta Therapeutics, NKARTA, Novartis, Orbita: Consultancy. Garcia-Manero: Genentech: Research Funding; Bristol Myers Squibb: Other: Medical writing support, Research Funding; AbbVie: Research Funding. Kordasti: Novartis: Honoraria, Membership on an entity's Board of Directors or advisory committees; MorphoSys: Research Funding; Beckman Coulter: Honoraria. Santini: BMS, Abbvie, Geron, Gilead, CTI, Otsuka, servier, janssen, Syros: Membership on an entity's Board of Directors or advisory committees. Kern: MLL Munich Leukemia Laboratory: Current Employment, Other: Equity Ownership. Platzbecker: Curis: Consultancy, Research Funding; Jazz: Consultancy, Honoraria, Research Funding; Geron: Consultancy, Research Funding; Merck: Research Funding; Silence Therapeutics: Consultancy, Honoraria, Research Funding; MDS Foundation: Membership on an entity's Board of Directors or advisory committees; Celgene: Honoraria; Takeda: Consultancy, Honoraria, Research Funding; Janssen Biotech: Consultancy, Research Funding; Roche: Research Funding; Syros: Consultancy, Honoraria, Research Funding; Servier: Consultancy, Honoraria, Research Funding; Fibrogen: Research Funding; AbbVie: Consultancy; Novartis: Consultancy, Honoraria, Research Funding; Bristol Myers Squibb: Consultancy, Honoraria, Membership on an entity's Board of Directors or advisory committees, Other: travel support; medical writing support, Research Funding; Amgen: Consultancy, Research Funding; BeiGene: Research Funding; BMS: Research Funding. Diez-Campelo: Gilead Sciences: Other: Travel expense reimbursement; Novartis: Consultancy, Honoraria, Membership on an entity's Board of Directors or advisory committees; BMS/Celgene: Consultancy, Honoraria, Membership on an entity's Board of Directors or advisory committees, Other: Advisory board fees; GSK: Consultancy, Membership on an entity's Board of Directors or advisory committees. Maciejewski: Regeneron: Consultancy, Honoraria; Alexion: Membership on an entity's Board of Directors or advisory committees; Novartis: Honoraria, Speakers Bureau; Omeros: Consultancy. Fenaux: Jazz: Consultancy, Honoraria, Research Funding; Janssen: Consultancy, Honoraria, Research Funding; Bristol Myers Squibb: Consultancy, Honoraria, Research Funding; Novartis: Consultancy, Honoraria, Research Funding; AbbVie: Consultancy, Honoraria, Research Funding; French MDS Group: Honoraria. Haferlach: MLL Munich Leukemia Laboratory: Current Employment, Other: Equity Ownership. Zeidan: Zentalis: Consultancy, Honoraria; Orum: Consultancy, Honoraria; Shattuck Labs: Research Funding; Novartis: Consultancy, Honoraria; Incyte: Consultancy, Honoraria; Foran: Consultancy, Research Funding; Janssen: Consultancy, Honoraria; Ionis: Consultancy, Honoraria; Takeda: Consultancy, Honoraria; Agios: Consultancy, Honoraria; BeyondSpring: Consultancy, Honoraria; Geron: Consultancy, Honoraria; Taiho: Consultancy, Honoraria; Mendus: Consultancy, Honoraria; Lox Oncology: Consultancy, Honoraria; Astellas: Consultancy, Honoraria; Syros: Consultancy, Honoraria; ALX Oncology: Consultancy, Honoraria; Chiesi: Consultancy, Honoraria; BioCryst: Consultancy, Honoraria; Notable: Consultancy, Honoraria; Gilead: Consultancy, Honoraria; Jazz: Consultancy, Honoraria; Epizyme: Consultancy, Honoraria; Syndax: Consultancy, Honoraria; Schrödinger: Consultancy, Honoraria; Regeneron: Consultancy, Honoraria; Tyme: Consultancy, Honoraria; Servier: Consultancy, Honoraria; Pfizer: Consultancy, Honoraria; Astex: Research Funding; Amgen: Consultancy, Honoraria; Boehringer-Ingelheim: Consultancy, Honoraria; AbbVie: Consultancy, Honoraria; Daiichi Sankyo: Consultancy, Honoraria; Celgene/BMS: Consultancy, Honoraria; Kura: Consultancy, Honoraria; Genentech: Consultancy, Honoraria; Otsuka: Consultancy, Honoraria; Seattle Genetics: Consultancy, Honoraria. Komrokji: AbbVie, CTI biopharma, Jazz, Pharma Essentia, Servio: Honoraria, Membership on an entity's Board of Directors or advisory committees, Speakers Bureau; Geron: Consultancy; BMS: Honoraria, Membership on an entity's Board of Directors or advisory committees, Research Funding; Novartis: Membership on an entity's Board of Directors or advisory committees; *Rigel, Taiho, DSI:* Honoraria, Membership on an entity's Board of Directors or advisory committees. **Della Porta:** *Bristol Myers Squibb:* Honoraria, Membership on an entity's Board of Directors or advisory committees.

Figure 1. Optimal timing of transplantation in the learning cohort, according to a IPSS-R based-policy. The decision model based on microsimulation simulated a hypothetical randomized clinical trial where subjects are randomized to receive HSCT at different time points upon disease diagnosis. Results were used to estimate the average survival time over an 8-year time horizon (Restricted Mean Survival Time, RMST), for each combination of covariates. RMST estimates were compared among different transplantation policies thus determining the optimal transplantation policy.



HSCT Time from MDS diagnosis (Months)

Figure 2. Optimal timing of transplantation in the learning cohort, according to a IPSS-M based-policy.




Figure 1

Session 637

https://doi.org/10.1182/blood-2023-182194